BVP has invested in healthcare-related companies for more than two decades. Drawing on our investors’ experience in medicine, science, information technology, and management, BVP has backed developers of innovative therapeutics - Isis Pharmaceuticals (NASDAQ:ISIP) and Sirtris (NASDAQ:SIRT); providers of healthcare service - VistaCare (NASDAQ:VSTA) and U.S. Behavioral Health (acquired by United Healthcare, NYSE:UBH); and suppliers of healthcare information technology - GMIS (NASDAQ:GMIS) and Allscripts (NASDAQ:MDRX). As the world's healthcare needs increase, we relish the opportunity to support entrepreneurs who will create the innovations of tomorrow.
BVP's healthcare team has a diversity of industry experience and is currently looking for investment opportunities in the following areas:
- Healthcare Services - BVP’s investments in this area include such service providers as VistaCare (NASDAQ:VSTA), the operator of hospice services; U.S. Behavioral Health Services (acquired by Travelers, NYSE:TRV), a provider of outsourced mental health services; IPC The Hospitalist Company (NASDAQ:IPCM), which supplies professionals for in-patient care; and TravCorps (NASDAQ:CCRN), a medical-staffing service.
- Healthcare Information Technology - BVP has invested in companies like Allscripts (NASDAQ:MDRX), whose software automates routine medical-information gathering tasks; GMIS (NASDAQ:GMIS), which developed technology to automate medical insurance claims; and Netsmart Technologies (acquired by Genstar Capital), which is the leading software provider to mental- and behavioral-health facilities.
- Therapeutics - BVP has a long history of backing successful biotech and pharma companies, including Affymax (NASDAQ:AFFY), a developer of novel drugs to address kidney disease and cancer; Isis (NASDAQ:ISIS), creator of a new class of drugs; Sirtris (NASDAQ:SIRT), acquired by GlaxoSmithKline (NYSE:GSK), which has worked extensively with the helpful enzymes known as sirtuins; and Enzytech (acquired by Alkermes (NASDAQ:ALKS), developer of methods to deliver smaller doses of drugs directly to affected body sites.
- Diagnostics – A relatively new area of focus for BVP’s healthcare practice is the diagnostics sector. BVP believes that new advances in molecular biology and biomedical engineering make the potential “personalization of medicine” now possible. To this end, we are actively looking to invest in both content and technology platforms that deliver on this vision in an economical way for our healthcare system.